Mice. AID-deficient (Aicda −/− ) mice were a gift from T. Honjo. Wild-type BALB/c mice were from the Jackson Laboratory. All animals were maintained according to the guidelines for animal welfare of the Memorial Sloan-Kettering Research Animal Resource Center.
The splicing regulator PTBP2 interacts with the cytidine deaminase AID and promotes binding of AID to switch-region DNA Urszula Nowak 1 , Allysia J Matthews 1 , Simin Zheng 1 & Jayanta Chaudhuri 1, 2 During immunoglobulin class-switch recombination (CSR), the cytidine deaminase AID induces double-strand breaks into transcribed, repetitive DNA elements called switch sequences. The mechanism that promotes the binding of AID specifically to switch regions remains to be elucidated. Here we used a proteomic screen with in vivo biotinylation of AID to identify the splicing regulator PTBP2 as a protein that interacts with AID. Knockdown of PTBP2 mediated by short hairpin RNA in B cells led to a decrease in binding of AID to transcribed switch regions, which resulted in considerable impairment of CSR. PTBP2 is thus an effector of CSR that promotes the binding of AID to switch-region DNA.
In developing B cells in the bone marrow, variable-diversity-joining (V(D)J) recombination assembles the gene segments encoding the amino terminus V region of the immunoglobulin heavy chain (IgH) upstream of the C µ constant-region gene segment 1 . The VDJ-Cµ heavy chain produced from this recombined Igh locus pairs with a similarly assembled κor λ-light chain to generate an IgM molecule that is expressed on mature, naive B cells. In secondary lymphoid organs such as the spleen and lymph nodes, the mature B cell meets antigens and undergoes Igh class-switch recombination (CSR), a process by which the C µ region is exchanged for one of several downstream constant region heavy-chain (C H ) genes (C γ , C ε or C α ). Thus, the B cell switches from producing IgM to producing a secondary antibody isotype such as IgG, IgE or IgA, each with a different effector function 2 .
CSR occurs between repetitive G:C-rich DNA elements 1-12 kilobases in length, called switch (S) regions, that precede each C H region 2 . Each of the C H gene segments is an individual transcription unit in which a cytokine-inducible promoter drives transcription through an intervening intronic exon, the intronic S region and the C H gene exons 2 . The primary transcript is spliced and polyadenylated; however, this mature germline transcript does not encode any protein 2 . Nevertheless, transcription has a major mechanistic role in CSR, as mutations that inhibit germline transcription also impair CSR 3 . It has been proposed that transcription through the S regions generates R-loop structures in which the G-rich nontemplate strand is looped out as single-stranded DNA (ssDNA), providing an ideal substrate for cytidine deamination mediated by AID 3 . The deamination of cytidines to uridines by AID in S regions mobilizes base-excision and mismatch-repair proteins to the deaminated DNA and leads to formation of DNA double-strand breaks 4 . Ligation of such breaks between two S regions by components of the general end-joining machinery completes CSR 3 .
During an immune response, mature B cells in secondary lymphoid organs undergo another AID-mediated DNA-alteration reaction, somatic hypermutation 5, 6 . In this process, AID deamination at the V regions of the recombined heavy-and light-chain genes leads to the generation of B cells with greater affinity for antigen 7 . Thus, in B cells, the V-region genes and S-region DNA constitute the two physiological targets of AID. However, AID can mutate other transcribed genes, albeit at a much lower rate than it mutates V-region genes 8 , and induce double-strand breaks at non-immunoglobulin regions 9, 10 . Such activity of AID at non-immunoglobulin regions is the main underlying cause of the oncogenic mutations and translocations that are the hallmark of mature B cell lymphomas 10 . How AID is targeted to the immunoglobulin regions is thus a major unanswered question.
It has been hypothesized that the recruitment of AID to S regions relies on the ability of AID to bind factors that in turn can bind to regions of the Igh locus 11 . Many proteins that interact with AID have been reported, including RPA 12 , Mdm2 (ref. 13 ) and CTNNBL1 (ref. 14) . However, none of these could be classified as an AID-targeting factor, as alteration of the sequence of these proteins or the inability of AID to interact with these proteins is not known to alter the binding of AID to its physiological targets. In a hunt for factors that target AID to S-region DNA, we did a proteomic screen and have identified PTBP2 as another protein that interacts with AID and influences CSR by promoting the binding of AID to S-region DNA.
RESULTS

Purification of AID complexes
To purify AID complexes, we used an in vivo biotinylation system that relies on the activity of the Escherichia coli biotin ligase BirA to biotinylate any target protein with a short sequence tag (biotag) when the two are expressed together in a cell line (Fig. 1a) . The biotinylated protein can then be affinity purified along with its interacting proteins with streptavidin beads 15 . For in vivo biotinylation of AID, we used a previously characterized 16 catalytically inactive AID (DM-AID) with two point substitutions (H56R and E58Q) in the deaminase domain (Fig. 1a) . The catalytically inactive AID has the potential to trap interacting proteins that would otherwise dissociate after deamination. To isolate AID complexes, we used the mouse CH12 B cell line, which switches in culture from IgM to IgA after stimulation with antibody to CD40 (anti-CD40), interleukin 4 (IL-4) and transforming growth factor-β (TGF-β; inducing conditions called 'CIT' here) 17 . Using CH12 cells for purification increases the opportunity for trapping relevant AID complexes in the process of mediating CSR.
We subcloned cells coexpressing BirA and biotag-labeled DM-AID (CH12(BirA-biotag-DM-AID)) by serial dilution and characterized them. We used CH12 cells expressing BirA alone (CH12(BirA)) as negative controls. Immunoblot analysis of cytoplasmic and nuclear extracts derived from CIT-stimulated CH12(BirA-biotag-DM-AID) and CH12(BirA) cells showed that the tagged AID protein, which could be distinguished from the endogenous protein because of its slower mobility through SDS gels, was not grossly overexpressed relative to endogenous AID ( Fig. 1b) . We detected the tagged protein in both the cytoplasm and the nucleus, with a nuclear/cytoplasmic ratio roughly similar to that observed for wildtype AID (Fig. 1b) . To ensure that biotinylated biotag-DM-AID could be affinity purified, we incubated extracts of CH12(BirAbiotag-DM-AID) cells with streptavidin agarose. Immunoblot analysis showed that AID was retained on the streptavidinagarose column and was biotinylated ( Fig. 1c ). Finally, we tested if biotag-DM-AID in CH12(BirA-biotag-DM-AID) cells could bind to S-region DNA. We affinity purified crosslinked DNA-protein complexes with streptavidin beads and analyzed the recovered DNA by PCR ( Fig. 1d) . We readily detected DNA from the µ-S region (S µ ), A r t i c l e s but not from the neighboring µ-promoter (I µ ), which indicated that biotag-DM-AID could specifically bind S-region DNA. Notably, although biotag-DM-AID was abundantly present in unstimulated CH12 cells ( Supplementary Fig. 1) , it required CIT stimulation for binding to S-region DNA (Fig. 1d) . This observation identified a hitherto unrecognized requirement for B cell stimulation in the interaction of AID with its target sequence. Overall, the proper intracellular localization of biotinylated biotag-DM-AID and its binding to S regions after stimulation confirmed the utility of this system in screening for AID-interacting proteins. We prepared nuclear extracts from CIT-stimulated CH12(BirAbiotag-DM-AID) and CH12(BirA) cells and subjected them to streptavidin-agarose affinity purification. We analyzed a fraction of the eluted protein by immunoblot to confirm the presence of biotag-DM-AID ( Supplementary Fig. 2 ). We partially resolved the remainder by electrophoresis through an SDS gel (Supplementary Fig. 3 ) and identified proteins present in the samples by liquid chromatographytandem mass spectrometry. The most abundant proteins detected were present in both CH12(BirA-biotag-DM-AID) and CH12(BirA) samples. These were metabolic proteins (such as acetyl-coA carboxylase 1, pyruvate carboxylase and propionyl-coA carboxylase) that are naturally biotinylated in the cell. Among those unique to the CH12(BirAbiotag-DM-AID) sample, we found 38 proteins that were common to two independent affinity-purification-mass spectrometry analyses ( Supplementary Table 1 ).
Approximately 30% of the proteins that potentially interacted with AID had undesignated functions. We detected several cytoskeletal and metabolic proteins and, notably, DNA-repair proteins, transcription factors, chromatin-remodeling proteins and mRNA-processing factors in the complex. We sought to confirm the putative interacting proteins individually in coimmunoprecipitation assays, starting with DNA-repair and mRNA-processing proteins, given the intricate links among AID, CSR and RNA-or DNA-dependent reactions. We immunoprecipitated AID from activated splenic B cells (wild-type cells, AID-deficient cells or AID-deficient cells expressing hemagglutinin-tagged AID) with anti-AID or anti-hemagglutinin and probed the immunoprecipitate for the presence of the proteins that putatively interact with AID. We did not detect DNA ligase I, transportin I or the DNA damage-repair protein Rad50 in the AID immunoprecipitates ( Supplementary Fig. 4 ), which indicated that either these proteins represented false positives in the mass spectrometry or they interact with AID in a way that occluded the antibodybinding site on AID during immunoprecipitation. Alternatively, as the original screen used catalytically inactive AID with the objective of creating a trap for complexes, these interactions may be too transient to detect by simple coimmunoprecipitation techniques. However, we readily detected DNA topoisomerase IIβ in the AID immunocomplex ( Supplementary Figs. 4 and 5) . Determining the physiological relevance of the AID-topoisomerase IIβ interaction to CSR will require further studies.
AID interacts with the splicing regulator PTBP2 One molecule detected, albeit with only one identifiable peptide, in both sets of mass spectrometry analyses was the splicing regulator PTBP2. We readily detected this 56-kilodalton, mainly nuclear protein ( Supplementary Fig. 6 ) from wild-type splenic B cells but not from AID-deficient activated splenic B cells in an AID complex immunoprecipitated with anti-AID ( Fig. 1e) . Conversely, immunoprecipitation of PTBP2 from activated splenic B cells showed the presence of AID in the immunoprecipitate (Fig. 1f) . The interaction between PTBP2 and AID is probably independent of RNA, as recombinant histidine-tagged PTBP2 bound to AID purified from human embryonic kidney 293T cells even when the proteins were treated with an excess of RNase A (Supplementary Fig. 7) . Additionally, substitution of serine with alanine in the phosphorylation site at position 38 of AID 18-20 did not abolish interaction with PTBP2 ( Supplementary  Fig. 7) , which indicated that the binding was not dependent on AID phosphorylation. Finally, recombinant PTBP2 did not alter the in vitro ssDNA deaminase activity of purified AID (Supplementary Fig. 8) .
These results indicated that AID and PTBP2 were able to interact in primary B cells, that the interaction was not dependent on RNA or the phosphorylation status of AID at Ser38 and that PTBP2 did not alter the ssDNA deaminase activity of AID.
PTBP2 is reported to be expressed mainly in mitotic neurons during neuronal development 21 . Its role in splicing has been inferred from its homology to PTBP1 (also known as PTB and hnRNP I). PTBP1 is ubiquitously expressed and is one of the best-studied splicing regulators. PTBP1 and PTBP2 are generally considered repressive regulators of splicing that bind RNA with polypyrimidine tracts, block spliceosome assembly at the site and mediate exon exclusion during alternative splicing 22, 23 . Notably, both polypyrimidine tracts and splicing have been linked to CSR. Alterations in protein sequence that block splicing of germline transcripts abrogate CSR, which indicates that the splicing machinery or the spliced transcripts influence CSR 24 . Additionally, S regions are transcribed in both the sense and antisense orientation, and the antisense transcripts are pyrimidine rich 25 . Those observations in conjunction with our findings here that PTBP2 does interact with AID in B cells led us to investigate the requirement for PTBP2 in CSR.
PTBP2 knockdown impairs CSR in CH12 cells
We used short hairpin RNA (shRNA) to stably knock down PTBP2 in CH12 cells. For this, we used the lentiviral vector pLKO-1, which transcribes the cloned shRNA from a U6 promoter. The pLKO-1 vector also contains a gene encoding puromycin resistance, which allows selection of cells with stable integration of shRNA constructs. We used two different shRNA constructs to knock down PTBP2, one directed against the coding sequence (PTBP2-1) and the other directed against the 3′ untranslated region of PTBP2 mRNA (PTBP2-2). We used a scrambled shRNA sequence that does not target any known eukaryotic mRNA as a control. We stimulated the puromycin-resistant cells for 72-96 h in culture in CIT conditions and then assayed PTBP2 expression by immunoblot analysis and CSR to IgA by flow cytometry. Both PTBP2-1 and PTBP2-2 led to much less PTBP2 protein in unstimulated cells and cells stimulated with CIT ( Fig. 2a) . When we used CIT to stimulate cells in which PTBP2 was knocked down and analyzed the cells by flow cytometry, we observed a considerable defect in CSR to IgA (Fig. 2b,c, Table 1 and Supplementary  Fig. 9 ). Although on average 28% of control cells underwent CSR to IgA, we observed only around 8% CSR in cells in which PTBP2 was knocked down (Fig. 2b,c, Table 1 and Supplementary Fig. 9 ). The defect in CSR was also evident from measurement of the steady state I α -C µ circle transcripts generated from the excised DNA after recombination between S µ and S α (Fig. 2d) . To ensure that the defect in CSR was a direct consequence of PTBP2 knockdown and was not due to nonspecific activity of the introduced shRNA, we expressed PTBP2 cDNA from a lentiviral vector in CH12 cells in which the endogenous protein was knocked down with the shRNA directed against its 3′ untranslated region (PTBP2-2). We observed that the restoration of PTBP2 expression ( Fig. 2e) restored CSR in the CH12 cells (Fig. 2f) . Overall, these results suggest that depletion of PTBP2 inhibits CSR.
Knockdown of PTBP2 did not substantially impair cell proliferation, as measured by the dilution of the permanent red dye SNARF over 48 h (Supplementary Fig. 10) . As CSR is linked to cell division 26 , we analyzed division-dependent CSR in greater detail. We stained control cells and cells in which PTBP2 was knocked down evenly with SNARF and stimulated the cells with CIT. After 72 h of stimulation, we separated the control cells into approximately 20th-percentile gates on the basis of SNARF expression. We then applied those gates to the cells infected with PTBP2-specific shRNA and quantified the frequency of IgA + cells in the gates. Regardless of the extent of proliferation as measured by SNARF dilution, the cells depleted of PTBP2 had consistently less CSR than did control cells (Supplementary Fig. 11) . Thus, knockdown of PTBP2 does not impair B cell proliferation, and in this experiment, the cells depleted of PTBP2 seemed to proliferate slightly faster. We conclude that the defect in CSR in cells in which PTBP2 was knocked down was not due to a defect in cell proliferation.
PTBP2 does not influence AID expression
Knockdown of PTBP2 did not have much effect on the steady-state abundance of µ-chain or α-chain germline transcripts ( Fig. 3 and  Supplementary Fig. 12 ). Likewise, depletion of PTBP2 did not alter the steady-state abundance of AID mRNA (Fig. 4a) or total AID protein ( Fig. 4b) . To ensure that PTBP2 does not influence the nuclear retention of AID, we analyzed by immunoblot analysis the abundance of AID protein in the nucleus of control cells and cells in which PTBP2 was knocked down. Although the absolute amount of total and nuclear AID varied between experiments, the ratio of AID to XRCC1, a nuclear protein used as a loading control, was similar in many experiments ( Fig. 4c and Supplementary Figs. 13 and 14) . To further demonstrate that knockdown of PTBP2 did not alter the nuclear retention of AID, we assessed ssDNA cytidine-deaminase activity in the nucleus as a fraction of total cellular AID activity (Fig. 4d) . Fig. 15 ). This activity was much greater in activated B cells that expressed AID (Fig. 4d) . Thus, ssDNA cytidinedeaminase activity in activated B cells is a convenient measure A r t i c l e s of AID activity 16 . Consistent with published reports 18 , approximately 25-30% of total AID was nuclear in control activated B cells, similar to that observed in cells in which PTBP2 was knocked down (Fig. 4e) . AID activity in the nucleus was not due to contamination by cytoplasmic AID, as we did not detect the cytoplasmic protein GAPDH in the nuclear fraction (Supplementary Fig. 16 ). Overall, we conclude that knockdown of PTBP2 did not affect either the abundance or nuclear retention of AID.
Unstimulated B cells had low basal ssDNA cytidine-deaminase activity (Supplementary
Depletion of PTBP2 impairs binding of AID to S regions PTBP2 is an RNA-binding protein. We therefore determined if recombinant PTBP2 could bind RNA transcribed from S-region DNA. We transcribed S regions or control DNA in vitro with T7 or SP6 RNA polymerase in the presence of [α-32 P]UTP. We incubated the radiolabeled RNA with immobilized recombinant histidine-tagged PTBP2 or the histidine-tagged control protein Gen1 on nickel-agarose beads and assessed the ability of the proteins to bind RNA as the retention of radioactive counts on the beads. As predicted from the affinity of PTBP family proteins for polypyrimidine-rich sequences, C-rich antisense S transcripts efficiently bound PTBP2 (Fig. 5) . Unexpectedly, RNA generated in vitro from S regions transcribed in the physiological orientation had 2.5-to 3-fold enrichment in binding to PTBP2 relative to that observed for non-S-region transcripts (Fig. 5) .
The ability of PTBP2 to bind S-region transcripts prompted us to use chromatin immunoprecipitation (ChIP) to determine if PTBP2 influences the ability of AID to bind transcribed S regions. We immunoprecipitated crosslinked DNA-protein complexes from CITstimulated CH12 cells with knockdown of PTBP2 or control CH12 cells with anti-AID and analyzed immunoprecipitated DNA for the presence of S µ . We used antibody to histone H3 and nonspecific IgG as positive and negative controls, respectively. We readily and specifically detected AID at S µ but not at the intronic µ-promoter, in control cells (Fig. 6) . Knockdown of PTBP2, however, led to much less AID associated with S µ (Fig. 6 and Supplementary Fig. 17) . These results indicate that depletion of PTBP2 substantially impaired either the recruitment or stable binding of AID to S regions.
PTBP2 influences CSR in primary B cells
The experiments described thus far investigated the ability of PTBP2 to mediate CSR specifically to IgA in the CH12 cell line. To determine if PTBP2 promotes CSR to IgG1 in primary B cells, we sought to deplete the protein in mouse splenic B cells. We transduced lentivirus encoding PTBP2-1 or PTBP2-2 into activated splenic B cells that we then stimulated with anti-CD40 and IL-4 in culture so they would undergo CSR to IgG1. Unlike knockdown in CH12 cells, in which drug selection over an extended period allowed us to generate cells that had stably integrated the shRNA constructs, the use of shRNA in primary splenic B cells is complicated by their limited lifespan in culture (4-6 d). Thus, depletion of the target protein might not reach the amount of depletion in CH12 cells before stimulation. We therefore included an additional control, an shRNA directed against AID, with the prediction that CSR in the cells in which AID was knocked down would serve as an indicator of the efficiency of shRNA knockdown in this system. PTBP2-1, PTBP2-2 and the AID-specific shRNA robustly depleted primary splenic B cells of the target proteins, as analyzed by immunoblot ( Fig. 7a) . Knockdown of PTBP2 did not influence the amount of AID in activated splenic B cells (Fig. 7a) . As predicted from the CSR defect in CH12 cells, knockdown of PTBP2 resulted in substantially impaired CSR to IgG1, as judged by both flow cytometry (Fig. 7b, Table 2 and Supplementary Fig. 18 ) and the abundance of I γ 1-C µ circle transcripts (Fig. 7c) , with the switching frequencies approaching that observed for AID knockdown. Notably, ChIP experiments showed that knockdown of PTBP2 in primary B cells led to considerably and significantly less AID associated with both S µ and S γ 1 DNA (Fig. 7d,e ). We used PCR analysis of p53 as a negative control for the ChIP experiment ( Supplementary Fig. 19 ). Overall, we conclude that the defect in CSR observed in cells depleted of PTBP2 was due mainly to less binding of AID to S-region DNA.
DISCUSSION
Here we have identified PTBP2 as an AID-interacting protein that has a pivotal role in CSR. PTBP2 and its closely related family member PTBP1 are RNA-binding proteins required for alternative splicing of precursor mRNA, a process critical for the generation of multiple protein isoforms from a single gene 27, 28 . PTBP2 was initially thought to be restricted to the brain and is therefore also known as brPTB (brain PTB) and nPTB (neuronal PTB) [29] [30] [31] . Subsequently, the protein has also been detected in testis and in small amounts in the liver, heart, lung, skeletal muscle and thymus 30 . To our knowledge, our findings are the first to describe PTBP2 expression in activated B cells. The mechanism of CSR has been closely linked to both germline transcription and splicing. The role of splicing in this reaction is enigmatic, as it is unclear whether components of the splicing machinery or the spliced transcripts themselves (or both) are required for CSR. At present, models of CSR posit that transcription generates ssDNA substrates for AID in the context of R-loops 32 . This R-loop-dependent model for CSR requires that the primary, unprocessed germline transcript stably hybridize to the template strand. If splicing occurs cotranscriptionally and efficiently, R-loop formation would be transient. It is conceivable that PTBP2 could be recruited to S-region DNA, maybe through interactions with modified histones 33 , and inhibit splicing, thus enhancing the stability of R-loops and facilitating CSR. Although the observation that the steady-state abundance of processed germline transcripts was not altered in the cells in which PTBP2 was knocked down would challenge the idea of such a role for PTBP2, we cannot rule out the possibility of transient alterations in the half-life of R-loop DNA in our studies.
The role of PTBP2 in CSR could be independent of its role in splicing. Our in vitro studies have shown that PTBP2 had the potential to bind both sense and antisense S-region transcripts, consistent with published reports that the PTBP family of proteins binds a wide variety of RNA 34 . Although transcription of S regions in the physiological orientation is essential for CSR, antisense transcripts encompassing S regions have also been reported 25 . It is therefore conceivable that PTBP2 can bind either sense or antisense S-region transcripts as they are being transcribed and recruit AID. Thus, the specificity of AID for binding to S regions is mediated by its ability to interact with PTBP2, which in turn binds to RNA emanating from the unique S regions. Recruitment of AID to S regions can also be mediated by Spt5, an RNA polymerase II-associated protein that interacts with AID 35 . Thus, multiple mechanisms operate to recruit AID to S-region DNA. The recruited AID could then be phosphorylated at Ser38 by protein kinase A, which associates with S-region DNA in an AID-independent way 36 . Phosphorylated AID then binds RPA at S-region DNA 12, 36 and the multicomponent complex thus formed could then trigger DNA deamination (by AID) and nucleation of downstream repair factors (by RPA), leading to the cascade of reactions that ultimately results in CSR.
We cannot exclude the possibility that PTBP2 influences CSR at multiple levels, including favorably altering the splicing of an unidentified protein required for the recruitment of AID. Additional work is needed to elucidate the precise function of PTBP2 in CSR. Likewise, the role, if any, of PTBP2 in somatic hypermutation needs to be determined. Nevertheless, the results presented here suggest that PTBP2 has the potential to shepherd AID to S regions during CSR and set the foundation for investigating how a known splicing regulator could promote AID targeting specificity.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. Flow cytometry analysis of CSR to IgG1 in activated B cells expressing control or AID-or PTBP2-specific shRNA. Data are from seven experiments.
